1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Metabolic Syndrome - Pipeline Review, H1 2014

Metabolic Syndrome - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 95 pages

Metabolic Syndrome - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Metabolic Syndrome - Pipeline Review, H1 2014’, provides an overview of the Metabolic Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metabolic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metabolic Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metabolic Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metabolic Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metabolic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metabolic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metabolic Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metabolic Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Metabolic Syndrome - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metabolic Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Metabolic Syndrome - Overview 10
Pipeline Products for Metabolic Syndrome - Comparative Analysis 11
Metabolic Syndrome - Therapeutics under Development by Companies 12
Metabolic Syndrome - Therapeutics under Investigation by Universities/Institutes 15
Metabolic Syndrome - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Metabolic Syndrome - Products under Development by Companies 21
Metabolic Syndrome - Products under Investigation by Universities/Institutes 22
Metabolic Syndrome - Companies Involved in Therapeutics Development 23
Dainippon Sumitomo Pharma Co., Ltd. 23
Ildong Pharmaceutical Co., Ltd. 24
Chipscreen Biosciences Ltd 25
Abeille Pharmaceuticals, Inc. 26
Cortendo Invest AB 27
Spherix Incorporated 28
Ache Laboratorios Farmaceuticos S/A 29
Indus Biotech Private Limited 30
Cardax Pharmaceuticals, Inc. 31
VivaCell Biotechnology Espana S.L. 32
Poxel SA 33
Shanghai Pharmaceuticals Holding Co Ltd 34
Lead Discovery Center GmbH 35
MI.TO. Technology S.r.L. 36
Metabolic Syndrome - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
CS-038 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
ACH-09 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
MBX-8025 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
chloroquine - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
eplerenone - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
SPX-10624258 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
MB-12066 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
AB-3001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
CDX-085 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
CDE-001 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
GQ-16 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Next Generation Cortisol Inhibitor - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
ND-630 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Drug Targeting AMPD2 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
KH-064 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Metabolic Syndrome Program - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Metabolic Syndrome Program - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Small Molecules for Inflammatory Diseases - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Myonectin - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
ID-2244 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
ZLN-024 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
C-24 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Drug Targeting Farnesoid X Receptor - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Apoptosis Inhibitor Of Macrophages - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Small Molecule for Cardiovascular And Metabolic Disorders - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
Drugs Targeting Acetyl-CoA Carboxylase - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
11 Beta Hydroxysteroid Dehydrogenase 1 Inhibitors - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Drug Targeting SIRT - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
TGR-5 Agonist Program - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
INDUS-810 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
Metabolic Syndrome - Recent Pipeline Updates 85
Metabolic Syndrome - Dormant Projects 87
Metabolic Syndrome - Discontinued Products 88
Metabolic Syndrome - Product Development Milestones 89
Featured News and Press Releases 89
Nov 11, 2013: Micardis crosses 50 million patient-years of experience on 15th anniversary 89
Aug 28, 2012: Cardax Pharma To Obtain Chinese Patent Protection For Lead Compound CDX-085 89
Apr 26, 2012: miRagen Announces Publication Of Data On MIRG-9103 In Journal Cell 90
Feb 27, 2012: Kadmon Announces Dosing Of First Patient In Phase I Study Of KD025 91
Sep 12, 2011: Cardiotrophin 1 Shows Promising Results For Treatment Of Obesity And Metabolic Syndrome 91
Jun 07, 2008: Orexigen Therapeutics Announces That Contrave May Reverse The Incidence Of Metabolic Syndrome 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95

List of Tables

Number of Products under Development for Metabolic Syndrome, H1 2014 10
Number of Products under Development for Metabolic Syndrome - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Investigation by Universities/Institutes, H1 2014 22
Metabolic Syndrome - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 23
Metabolic Syndrome - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2014 24
Metabolic Syndrome - Pipeline by Chipscreen Biosciences Ltd, H1 2014 25
Metabolic Syndrome - Pipeline by Abeille Pharmaceuticals, Inc., H1 2014 26
Metabolic Syndrome - Pipeline by Cortendo Invest AB, H1 2014 27
Metabolic Syndrome - Pipeline by Spherix Incorporated, H1 2014 28
Metabolic Syndrome - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 29
Metabolic Syndrome - Pipeline by Indus Biotech Private Limited, H1 2014 30
Metabolic Syndrome - Pipeline by Cardax Pharmaceuticals, Inc., H1 2014 31
Metabolic Syndrome - Pipeline by VivaCell Biotechnology Espana S.L., H1 2014 32
Metabolic Syndrome - Pipeline by Poxel SA, H1 2014 33
Metabolic Syndrome - Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, H1 2014 34
Metabolic Syndrome - Pipeline by Lead Discovery Center GmbH, H1 2014 35
Metabolic Syndrome - Pipeline by MI.TO. Technology S.r.L., H1 2014 36
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
Metabolic Syndrome Therapeutics - Recent Pipeline Updates, H1 2014 85
Metabolic Syndrome - Dormant Projects, H1 2014 87
Metabolic Syndrome - Discontinued Products, H1 2014 88

List of Figures
Number of Products under Development for Metabolic Syndrome, H1 2014 10
Number of Products under Development for Metabolic Syndrome - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.